secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nurix Therapeutics, Inc. (NRIX)
CIK:        0001549595
Form:       8-K
Filed at:   2026-10-13T10:19:25+00:00
Accession:  0001549595-26-000048
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Nurix Q3 FY26 revenue $673.1M on Roche collaboration; net income $549.8M, EPS $4.73
--------------------------------------------------------------------------------

- Revenue $673.1M vs $7.9M YoY, including $653.2M license revenue from Roche and a $10.0M Sanofi milestone.
- Net income $549.8M, or $4.73 per diluted share, vs an $86.4M net loss (-$1.03) a year ago; cash $1.1B with runway into H2 2029.
- Dosed first patient in Phase 3 DAYBreak CLL-306 testing bexobrutideg 600 mg vs pirtobrutinib in ~620 relapsed/refractory CLL/SLL patients; dual primary endpoints ORR and PFS.
- Phase 1a CLL data showed median PFS 22.1 months and 83.0% ORR; Phase 1b ORR 92.9% in BTK-pretreated/BCL2-naive patients.
- Discontinued NX-2127; NX-1607 entered Phase 1b in MSS CRC, NSCLC, CRPC and melanoma; Gilead extended a research term for a $10.0M fee.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1549595/000154959526000048/0001549595-26-000048-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1549595/000154959526000048/nrix-20261012.htm
  HTML page:      https://secwatch.observer/filing/0001549595-26-000048

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer